Industry ShowcaseLearn About COBENFY (xanomeline and trospium chloride): Where Does It Fit in Your Practice?Supported by Bristol Myers Squibb

Registration Options

Activity Date: 04/29/2025

Session Time and Location

Date: Tuesday, 04/29/2025

Time: 8:15 AM (view in the schedule)

Room: Salt Lake CD-L2

To view the session live, you will need to reload this page closer to when the session starts.

Session Summary

Don't miss this opportunity to learn about COBENFY as a treatment option for your patients. Explore COBENFY's clinical profile, including efficacy, safety, and dosing information. This program also highlights practical considerations when prescribing COBENFY.

Learning Objectives

Explore the persistent challenges and evolving understanding of schizophrenia.
Review the short- and long-term data supporting the efficacy, safety and tolerability profile of COBENFY.
Review practical considerations when prescribing COBENFY.

Faculty Information

Alberto Augsten, PharmD, MS, BCPP, DABAT

View biographical information

Continuing Education Credit and Disclosures

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

Grant Support

Supported by Bristol Myers Squibb